Safety and Tolerability of Tafluprost in Treatment of Elevated Intraocular Pressure in Open-angle Glaucoma and Ocular Hypertension

Overview

Journal Clin Ophthalmol

Publisher Dove Medical Press

Specialty Ophthalmology

Date 2010 Nov 10

PMID 21060677

Citations 3

Authors

Dorota Pozarowska

Affiliations

Soon will be listed here.

Abstract

Glaucoma is one of the most common neuropathies of the optic nerve. An elevated intraocular pressure (IOP) is a well documented risk factor for the development and progression of this disease. Until now, IOP reduction is the only well documented successful method of glaucoma treatment. Among the many hypotensive drugs, prostaglandin analogs are proved to be the most potent antiglaucoma agents, with very few systemic side effects. A new prostanoid FP receptor analog, tafluprost, has been introduced into the medical treatment of glaucoma and ocular hypertension. Many studies have shown that it is an efficient IOP-lowering drug, and that it is safe and well tolerated. A preservative-free tafluprost formulation is as potent as a preserved one, but it has fewer and milder toxic effects on the eye.

Citing Articles

Aluminum-catalyzed tunable halodefluorination of trifluoromethyl- and difluoroalkyl-substituted olefins.

Liu Z, Tu X, Guo L, Wang X Chem Sci. 2021; 11(42):11548-11553.

PMID: 34094400 PMC: 8162833. DOI: 10.1039/d0sc03883k.

A Novel Convergent Synthesis of the Potent Antiglaucoma Agent Tafluprost.

Krupa M, Chodynski M, Ostaszewska A, Cmoch P, Dams I Molecules. 2017; 22(2).

PMID: 28146132 PMC: 6155834. DOI: 10.3390/molecules22020217.

Comparison of Ocular Pulse Amplitude Lowering Effects of Preservative-Free Tafluprost and Preservative-Free Dorzolamide-Timolol Fixed Combination Eyedrops.

Seo D, Ha S Biomed Res Int. 2015; 2015:435874.

PMID: 26557671 PMC: 4628750. DOI: 10.1155/2015/435874.

References

Hommer A, Mohammed Ramez O, Burchert M, Kimmich F . IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma. Curr Med Res Opin. 2010; 26(8):1905-13. DOI: 10.1185/03007995.2010.492030. View

Munoz-Negrete F, Perez-Lopez M, Won Kim H, Rebolleda G . [New developments in glaucoma medical treatment]. Arch Soc Esp Oftalmol. 2009; 84(10):491-500. DOI: 10.4321/s0365-66912009001000003. View

Sutton A, Gouws P, Ropo A . Tafluprost, a new potent prostanoid receptor agonist: a dose-response study on pharmacodynamics and tolerability in healthy volunteers. Int J Clin Pharmacol Ther. 2008; 46(8):400-6. DOI: 10.5414/cpp46400. View

Hamacher T, Airaksinen J, Saarela V, Liinamaa M, Richter U, Ropo A . Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis. Acta Ophthalmol Suppl (Oxf ). 2008; 242:14-9. DOI: 10.1111/j.1755-3768.2008.01381.x. View

Miglior S, Torri V, Zeyen T, Pfeiffer N, Vaz J, Adamsons I . Intercurrent factors associated with the development of open-angle glaucoma in the European glaucoma prevention study. Am J Ophthalmol. 2007; 144(2):266-275. DOI: 10.1016/j.ajo.2007.04.040. View

Mietz H, Niesen U, Krieglstein G . The effect of preservatives and antiglaucomatous medication on the histopathology of the conjunctiva. Graefes Arch Clin Exp Ophthalmol. 1994; 232(9):561-5. DOI: 10.1007/BF00182000. View

Thygesen J . In search of improved prostaglandin treatment for glaucoma. Acta Ophthalmol Suppl (Oxf ). 2008; 242:5-6. DOI: 10.1111/j.1755-3768.2008.01379.x. View

Aihara M . Clinical appraisal of tafluprost in the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension. Clin Ophthalmol. 2010; 4:163-70. PMC: 2850830. DOI: 10.2147/opth.s6368. View

. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol. 1998; 126(4):498-505. DOI: 10.1016/s0002-9394(98)00272-4. View

10.

Uusitalo H, Kaarniranta K, Ropo A . Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers. Acta Ophthalmol Suppl (Oxf ). 2008; 242:7-13. DOI: 10.1111/j.1755-3768.2008.01380.x. View

11.

. The Advanced Glaucoma Intervention Study (AGIS): 12. Baseline risk factors for sustained loss of visual field and visual acuity in patients with advanced glaucoma. Am J Ophthalmol. 2002; 134(4):499-512. DOI: 10.1016/s0002-9394(02)01659-8. View

12.

Guenoun J, Baudouin C, Rat P, Pauly A, Warnet J, Brignole-Baudouin F . In vitro comparison of cytoprotective and antioxidative effects of latanoprost, travoprost, and bimatoprost on conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci. 2005; 46(12):4594-9. DOI: 10.1167/iovs.05-0776. View

13.

Uusitalo H, Pillunat L, Ropo A . Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study. Acta Ophthalmol. 2010; 88(1):12-9. DOI: 10.1111/j.1755-3768.2010.01862.x. View

14.

Chou S, Chou C, Kuang T, Hsu W . Incidence and severity of iris pigmentation on latanoprost-treated glaucoma eyes. Eye (Lond). 2004; 19(7):784-7. DOI: 10.1038/sj.eye.6701663. View

15.

Pellinen P, Lokkila J . Corneal penetration into rabbit aqueous humor is comparable between preserved and preservative-free tafluprost. Ophthalmic Res. 2009; 41(2):118-22. DOI: 10.1159/000192082. View

16.

Izumi N, Nagaoka T, Sato E, Mori F, Takahashi A, Sogawa K . Short-term effects of topical tafluprost on retinal blood flow in cats. J Ocul Pharmacol Ther. 2008; 24(5):521-6. DOI: 10.1089/jop.2007.0065. View

17.

Uusitalo H, Chen E, Pfeiffer N, Brignole-Baudouin F, Kaarniranta K, Leino M . Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol. 2010; 88(3):329-36. DOI: 10.1111/j.1755-3768.2010.01907.x. View

18.

Brasnu E, Brignole-Baudouin F, Riancho L, Guenoun J, Warnet J, Baudouin C . In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line. Curr Eye Res. 2008; 33(4):303-12. DOI: 10.1080/02713680801971857. View

19.

Yee R . The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a review. Curr Opin Ophthalmol. 2007; 18(2):134-9. DOI: 10.1097/ICU.0b013e328089f1c8. View

20.

Brasnu E, Brignole-Baudouin F, Riancho L, Warnet J, Baudouin C . Comparative study on the cytotoxic effects of benzalkonium chloride on the Wong-Kilbourne derivative of Chang conjunctival and IOBA-NHC cell lines. Mol Vis. 2008; 14:394-402. PMC: 2268853. View